Results 1 to 10 of about 53,515 (238)
Five-Year Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma [PDF]
BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial.
Lars Bastholt +2 more
exaly +2 more sources
Nivolumab Plus Ipilimumab Versus Sunitinib in Advanced Renal-Cell Carcinoma [PDF]
Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell ...
Nizar Tannir +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Overall Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma
New England Journal of Medicine, 2017James Larkin +2 more
exaly
Improved Survival With Ipilimumab in Patients With Metastatic Melanoma
New England Journal of Medicine, 2010Axel Hoos +2 more
exaly
Final, 10-Year Outcomes With Nivolumab Plus Ipilimumab in Advanced Melanoma
New England Journal of MedicineGeorgina V. Long +2 more
exaly

